Olema Pharmaceuticals, Inc.
Clinical trials sponsored by Olema Pharmaceuticals, Inc., explained in plain language.
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New hope for advanced breast cancer: drug combo trial opens
Disease control Recruiting nowThis early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug OP-3136 enters first human tests
Disease control Recruiting nowThis early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have not responded to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The study will first find a safe dose, then test i…
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC